On August 24, 2026, the FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, to detect…
On August 24, 2026, the FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, to detect Alzheimer’s disease in adults 55+ with cognitive decline. The test measures pTau217 levels, aiding both rule-in and rule-out assessments of amyloid pathology. Experts highlight its simplicity, accuracy, and potential to improve diagnostic access.
How this was made
The 30-second read
Why it matters
The clearance could accelerate adoption of blood‑based diagnostics, benefiting both companies' revenue streams and supporting drug development pipelines.
Market read
First FDA‑cleared blood test that both rules‑in and rules‑out Alzheimer’s amyloid pathology, potentially reshaping diagnostic and therapeutic markets.
What to watch
Competition from existing tests and the need for real‑world performance data could moderate impact.
Background
The FDA cleared a single‑biomarker blood test (Elecsys pTau217) for detecting amyloid pathology in Alzheimer’s disease, co‑developed by Roche and Eli Lilly.
Ticker impact
FDA cleared the Elecsys pTau217 blood test co‑developed by Eli Lilly.
LLY may experience a modest positive reaction as the test supports its Alzheimer's pipeline.
The clearance validates Lilly's involvement in a breakthrough diagnostic, enhancing its market positioning.
Market effects
Strengthens the diagnostics and biotech sector's outlook for blood‑based Alzheimer’s tests.
U.S. healthcare market sees new FDA‑approved tool, potentially influencing global adoption.
Sets a precedent for blood‑based neurodegenerative disease diagnostics worldwide.
Counterpoint
The test may face reimbursement challenges and limited uptake, dampening upside.
Key entities
- CompanyRoche
Swiss pharmaceutical firm co‑developer of the test.
- CompanyEli Lilly
U.S. pharmaceutical firm co‑developer of the test.
- RegulatorU.S. Food & Drug Administration
Agency that granted clearance for the test.
